Assessment of ventilator-associated pneumonia by combining 8-isoprostane and nitric oxide levels in exhaled breath condensate with the clinical pulmonary infection score. Issue 5 (May 2020)

• Record Type: Journal Article
• Authors: Jin, Zhaoquan; Zhang, Wenbin; Zhu, Minghui; Xu, Juxian; Deng, Guohua; Wang, Daming
• Is Part Of: Journal of international medical research. Volume 48:Issue 5(2020)
• Publication Date: 2020-05
• Subjects: Exhaled breath condensate -- ventilator-associated pneumonia -- clinical pulmonary infection score -- 8-isoprostane -- nitric oxide -- lung injury score -- chest X-ray score; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060520922472
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To investigate the effectiveness of combining the 8-isoprostane and nitric oxide (NO) levels in exhaled breath condensate (EBC) with the clinical pulmonary infection score (CPIS) to assess ventilator-associated pneumonia (VAP) in patients on mechanical ventilation. Methods: Thirty-two patients with VAP served as the observation group and 32 patients without VAP served as the control group. The correlations of 8-isoprostane and NO levels in EBC with CPIS, chest X-ray score, oxygenation index, and lung injury score (LIS) were analyzed. The area under the curve (AUC) was compared with experimental data using the receiver operating characteristic curve (ROC) to predict VAP. Results: The 8-isoprostane and NO levels in EBC of VAP patients on mechanical ventilation were positively correlated with CPIS, chest X-ray score, and LIS, but negatively correlated with oxygenation index. The AUC of simplified CPIS combined with 8-isoprostane and NO levels in EBC for predicting VAP was 0.914, which suggests that this is a highly effective for making a diagnosis. Conclusions: The simplified CPIS combined with the 8-isoprostane and NO levels in EBC of patients on mechanical ventilation is effective for evaluating and diagnosing VAP. 8-Isoprostane and NO levels in EBC could be used as biomarkers to evaluate VAP.